Related Experiment Video
Updated: Aug 4, 2026

07:29
Programmed Electrical Stimulation in Mice
Published on: May 26, 2010
Long-term thresholds of nonsteroidal permanent pacing leads: a 5-year study
T P Gumbrielle1, J P Bourke, M Sinkovic
1Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
Pacing and Clinical Electrophysiology : PACE
|May 1, 1996
Summary
Three types of nonsteroidal endocardial pacing leads showed similar long-term performance in VVI implants. Lead selection can prioritize cost due to comparable pacing and sensing capabilities over five years.
Area of Science:
- Cardiology
- Biomedical Engineering
- Medical Device Technology
Background:
- The market offers various nonsteroidal endocardial pacing leads.
- Understanding long-term performance differences is crucial for clinical decision-making.
Purpose of the Study:
- To compare the long-term pacing and sensing performance of three representative nonsteroidal endocardial lead types.
- To evaluate lead performance over a 5-year follow-up period in patients with VVI implants.
Main Methods:
- A randomized clinical trial involving 99 patients undergoing VVI implantation.
- Three lead types were used: sintered platinum, activated pyrolytic carbon, and vitreous carbon.
- Noninvasive voltage thresholds and acute sensing parameters were monitored for 5 years.
Main Results:
- No significant differences in pacing or sensing capabilities were found at implantation among the three lead types.
- All leads showed similar threshold increases, peaking at 1 month and plateauing by 6 months.
- No significant differences in thresholds were observed between leads during the 5-year follow-up, with a mean threshold of 0.93 V at 0.5 ms at 5 years.
Conclusions:
- All tested lead types perform well without distinct clinical advantages over each other.
- Early threshold peaking necessitates delayed output reduction, while later stable thresholds allow for pacing output adjustments.
- Safe low-energy pacing requires careful consideration of lead-generator combinations.
- Annual follow-up beyond 1 year provided limited additional clinical information.
- Cost becomes a primary factor in lead selection when performance is comparable.

